Influenza Testing Market: By Test Type (Traditional Diagnostic Tests, Molecular Diagnostic Tests), Product (Point-Of-Care Testing, Immunodiagnostics, Molecular Diagnostics), Type-of-Flu (Type A Flu, Type B Flu, Type C Flu), End User (Hospitals/Clinical Laboratories, Reference Laboratories, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and forecast to 2030

Influenza Testing Market was valued at USD 2,673.3 million in 2023 and is expected to grow at an 6.1% CAGR from 2024 to 2030. Influenza is a communicable flu that is caused by a virus and spreads when people come in contact with the affected person. Influenza testing is generally done to check the main reason for the disease and proper diagnosis is being started to cure the patient. The growing incidence of influenza diseases due to the influenza virus and rising demand for rapid disease diagnosis are the significant factors responsible for driving the growth of the influenza testing market. For instance, in September 2022, National Influenza Centres and other laboratories from 102 countries tested over 112,017 specimens between 22^nd August 2022 to 4^th September 2022. Out of those, 3,879 tested positive for influenza viruses. Additionally, the increasing focus on quality of healthcare along with the growing concern of faster diagnosis and influenza control also heighten the overall growth of the influenza testing market.

However, factors such as the high cost included in influenza testing procedures obstruct the influenza testing market’s growth in the forecast period. On the other hand, the stringent regulatory framework has the potential to challenge the influenza testing market. Furthermore, the growth in influenza research for diagnostic technologies is expected to generate profitable opportunities for the influenza testing market. Moreover, the growing availability of point-of-care testing (POCT) in the area of rapid diagnostics of infectious diseases including flu, is expected to increase the demand for influenza testing in developing countries. For instance, a study was conducted in October 2022, to assess the POCT scope for infectious diseases in European countries. As per the study, under surveillance, POCT is widely used for infectious diseases with significant incidence rates, such as HIV and flu. Clinical research funding and expenditures in this field help to increase the scope of the projects that are done as well as the number of people engaged. Governments, the private sector, and businesses all provide money for research and development. For instance, in September 2019, the Collaboration Influenza Vaccine Innovations Centers (CIVICs) programme was launched by the National Institute of Allergy and Infectious Diseases (NIAID), a division of National Institutes of Health.

Recent Market Developments:

• In August 2023, the U.S. FDA granted 510(k) clearance to a respiratory viral panel (RVP) developed by BD for the identification of patients with COVID-19, flue, and respiratory syncytial virus (RSV)
• In February 2023, the U.S. FDA granted emergency use of authorization approval for Lucira COVID-19 & Flu Home Test developed by Pfizer Inc. to diagnose influenza viruses A and B. It is an over-the-counter (OTC) at-home diagnostic test.
• In October 2022, Hologic Inc. launched its Aptima SARS-CoV-2/Flue test in Europe and North America. This approval is expected to drive market growth in both regions.